Selected research
Industry Growth & Trends
Global Cancer Pain Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Cancer Pain market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cancer Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Cancer Pain market include Teva pharmaceuticals, Sanofi, Johnson＆Johnson, Eli-Lilly, WEX Pharmaceuticals, ProStrakan Group, Orexo, Meda Pharmaceuticals and GW Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cancer Pain market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cancer Pain market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Pain market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Pain.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Cancer Pain market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cancer Pain Market by Company
Teva pharmaceuticals
Sanofi
Johnson＆Johnson
Eli-Lilly
WEX Pharmaceuticals
ProStrakan Group
Orexo
Meda Pharmaceuticals
GW Pharmaceuticals
Grunenthal Group
BioDelivery Science
Cancer Pain Segment by Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
Cancer Pain Segment by Application
Hormone Therapy
Chemotherapy
Radiotherapy
Others
Cancer Pain Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Cancer Pain companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Opioids
- Non-Steroidal Anti-Inflammatory Drugs
- Others
Applications
- Hormone Therapy
- Chemotherapy
- Radiotherapy
- Others
Companies covered
- Teva pharmaceuticals
- Sanofi
- Johnson＆Johnson
- Eli-Lilly
- WEX Pharmaceuticals
- ProStrakan Group
- Orexo
- Meda Pharmaceuticals
- GW Pharmaceuticals
- Grunenthal Group
- BioDelivery Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Cancer Pain Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Cancer Pain Market Size by Region (2021-2032)
- 1.4.1 Global Cancer Pain Market Size by Region (2021-2026)
- 1.4.2 Global Cancer Pain Market Size by Region (2027-2032)
- 1.5 Key Regions Cancer Pain Market Size (2021-2032)
- 1.5.1 North America Cancer Pain Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Cancer Pain Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Cancer Pain Market Size Growth Rate (2021-2032)
- 1.5.4 South America Cancer Pain Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Cancer Pain Market Size Growth Rate (2021-2032)
2 Cancer Pain Market by Type
- 2.1 Type Introduction
- 2.1.1 Opioids
- 2.1.2 Non-Steroidal Anti-Inflammatory Drugs
- 2.1.3 Others
- 2.2 Global Cancer Pain Market Size by Type
- 2.2.1 Global Cancer Pain Market Size Overview by Type (2021-2032)
- 2.2.2 Global Cancer Pain Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Cancer Pain Market Size Forecasted by Type (2027-2032)
- 2.3 Global Cancer Pain Market Size by Regions
- 2.3.1 North America Cancer Pain Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Cancer Pain Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Cancer Pain Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Cancer Pain Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Cancer Pain Market Size Breakdown by Type (2021-2026)
3 Cancer Pain Market by Application
- 3.1 Type Introduction
- 3.1.1 Hormone Therapy
- 3.1.2 Chemotherapy
- 3.1.3 Radiotherapy
- 3.1.4 Others
- 3.2 Global Cancer Pain Market Size by Application
- 3.2.1 Global Cancer Pain Market Size Overview by Application (2021-2032)
- 3.2.2 Global Cancer Pain Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Cancer Pain Market Size Forecasted by Application (2027-2032)
- 3.3 Global Cancer Pain Market Size by Regions
- 3.3.1 North America Cancer Pain Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Cancer Pain Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Cancer Pain Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Cancer Pain Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Cancer Pain Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Cancer Pain Industry Trends
- 4.2 Cancer Pain Industry Drivers
- 4.3 Cancer Pain Industry Opportunities and Challenges
- 4.4 Cancer Pain Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Cancer Pain Revenue (2021-2026)
- 5.2 Global Cancer Pain Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Cancer Pain Key Company Headquarters & Area Served
- 5.4 Global Cancer Pain Company, Product Type & Application
- 5.5 Global Cancer Pain Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Cancer Pain Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Cancer Pain Players Market Share by Revenue in 2025
- 5.6.3 2025 Cancer Pain Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva pharmaceuticals
- 6.1.1 Teva pharmaceuticals Company Information
- 6.1.2 Teva pharmaceuticals Business Overview
- 6.1.3 Teva pharmaceuticals Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva pharmaceuticals Cancer Pain Product Portfolio
- 6.1.5 Teva pharmaceuticals Recent Developments
- 6.2 Sanofi
- 6.2.1 Sanofi Company Information
- 6.2.2 Sanofi Business Overview
- 6.2.3 Sanofi Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sanofi Cancer Pain Product Portfolio
- 6.2.5 Sanofi Recent Developments
- 6.3 Johnson＆Johnson
- 6.3.1 Johnson＆Johnson Company Information
- 6.3.2 Johnson＆Johnson Business Overview
- 6.3.3 Johnson＆Johnson Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Johnson＆Johnson Cancer Pain Product Portfolio
- 6.3.5 Johnson＆Johnson Recent Developments
- 6.4 Eli-Lilly
- 6.4.1 Eli-Lilly Company Information
- 6.4.2 Eli-Lilly Business Overview
- 6.4.3 Eli-Lilly Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Eli-Lilly Cancer Pain Product Portfolio
- 6.4.5 Eli-Lilly Recent Developments
- 6.5 WEX Pharmaceuticals
- 6.5.1 WEX Pharmaceuticals Company Information
- 6.5.2 WEX Pharmaceuticals Business Overview
- 6.5.3 WEX Pharmaceuticals Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 WEX Pharmaceuticals Cancer Pain Product Portfolio
- 6.5.5 WEX Pharmaceuticals Recent Developments
- 6.6 ProStrakan Group
- 6.6.1 ProStrakan Group Company Information
- 6.6.2 ProStrakan Group Business Overview
- 6.6.3 ProStrakan Group Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 ProStrakan Group Cancer Pain Product Portfolio
- 6.6.5 ProStrakan Group Recent Developments
- 6.7 Orexo
- 6.7.1 Orexo Company Information
- 6.7.2 Orexo Business Overview
- 6.7.3 Orexo Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Orexo Cancer Pain Product Portfolio
- 6.7.5 Orexo Recent Developments
- 6.8 Meda Pharmaceuticals
- 6.8.1 Meda Pharmaceuticals Company Information
- 6.8.2 Meda Pharmaceuticals Business Overview
- 6.8.3 Meda Pharmaceuticals Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Meda Pharmaceuticals Cancer Pain Product Portfolio
- 6.8.5 Meda Pharmaceuticals Recent Developments
- 6.9 GW Pharmaceuticals
- 6.9.1 GW Pharmaceuticals Company Information
- 6.9.2 GW Pharmaceuticals Business Overview
- 6.9.3 GW Pharmaceuticals Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 GW Pharmaceuticals Cancer Pain Product Portfolio
- 6.9.5 GW Pharmaceuticals Recent Developments
- 6.10 Grunenthal Group
- 6.10.1 Grunenthal Group Company Information
- 6.10.2 Grunenthal Group Business Overview
- 6.10.3 Grunenthal Group Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Grunenthal Group Cancer Pain Product Portfolio
- 6.10.5 Grunenthal Group Recent Developments
- 6.11 BioDelivery Science
- 6.11.1 BioDelivery Science Company Information
- 6.11.2 BioDelivery Science Business Overview
- 6.11.3 BioDelivery Science Cancer Pain Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 BioDelivery Science Cancer Pain Product Portfolio
- 6.11.5 BioDelivery Science Recent Developments
7 North America
- 7.1 North America Cancer Pain Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Cancer Pain Market Size by Country (2021-2026)
- 7.3 North America Cancer Pain Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Cancer Pain Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Cancer Pain Market Size by Country (2021-2026)
- 8.3 Europe Cancer Pain Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Cancer Pain Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Cancer Pain Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Cancer Pain Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Cancer Pain Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Cancer Pain Market Size by Country (2021-2026)
- 10.3 South America Cancer Pain Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Cancer Pain Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Cancer Pain Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Cancer Pain Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst